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Abstract  
 
A strong association between Human Papilloma Virus (HPV) and the 
development of pre-invasive and invasive lesions of the uterine cervix has been 
established. 
Rates of cervical cancer and its precursor are significantly higher in women with 
Human Immunodeficiency Virus (HIV) and/or AIDS than in the general 
population.  
The aim of this study is to investigate the mid and long–term impact of Highly 
Active Antiretroviral Therapy (HAART) treatment in a cohort of woman with 
HPV and HIV in Mozambique.  
The study was conducted in the context of the DREAM Programme in 
Mozambique, in collaboration with the Department of Gynaecology and 
Department of Pathology of the Central Hospital of Maputo. 
This is a prospective observational study including HIV negative women and HIV 
positive women who had either started or had not started HAART. 
Three hundred and nineteen ( 319)  women were enrolled: 236 HIV positive and 
83 HIV negative; 
The risk of HPV infection was significantly higher among HIV infected women 
(RR=1.8; CL 1.3 -2.4). 
Severe lesions (CIN2/CIN3) correlated significantly with CD4 cell counts. 
The risk of CIN 2/3  lesions increase in patients with less than 200 CD4 cells was 
very high (X2=14.362; p=0.02) 
Our data confirm the potential role of HAART in protecting against cervical 
cancer in HIV positive patients.  
The immune reconstitution mediated by HAART enables an increase in CD4 cell 
counts and decreases the risk of developing of cervical cancer.  
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1. Introduction: 
1.1 Epidemiology, cause and risk factors for cervical cancer  
Cervical cancer is the second most common cancer in women globally. Over 50% 
of the women who develop cervical cancer will die from the disease. Cervical 
cancer is the leading cause of cancer death of adult women in the developing 
world (WHO Cervical cancer Human papilloma Virus (HPV), Geneva, 2007).  
 
 
 
Cervical cancer is caused by the Human Papillomavirus (HPV) viral infection 
(Palesfsky JM, et al 1998). 
HPV is the most frequent sexually transmitted infection in the sexually active 
population. Several studies have already clearly demonstrated this (Melnikow J et 
al, 1998, Odendal L, 2011) .  
Many studies performed in more than 20 countries identified HPV DNA in 
almost all (99.7%) of about 1,000 cases of cervical cancer (Bosch FX, Muñoz, N. 
2002, Walboomers JM, Jacobs MV, 1999). 
The extreme rarity of HPV-negative cancers reinforces the rationale for HPV 
testing in addition to cervical cytology in routine cervical screening. 
Over 100 subtypes of the HPV virus have  been identified. 
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Thirteen of these are considered to be high risk because they can cause cancer 
(Odendal L, 2011). 
Approximately 10% of HPV infections can progress to cancer (WHO Cervical 
cancer Human papilloma Virus (HPV) 2008). Pre-cancerous changes generally 
occur in the cells of the cervix. These lesions can progress to cancer, although this 
progression only occurs very rarely. (Melnikow J et al.1998) 
Pre-cancerous lesions are classified as Cervical Intraepithelial Neoplasia (CIN), 
Squamous Intraepithelial Lesion (SIL) and Dysplasia. 
The two cervical cancers are classified as Squamous Cell Carcinoma and 
Adenocarcinoma (ADC). The most frequent cancer is Squamous Cell Carcinoma 
(around 80-90%) (Odendal L, 2011). Persistence of HPV infection leads to the 
development of cervical cancer. The median time is estimated as 20 years and is 
typically divided  the following stages: 
 CIN of grade1 lesions, which can be resolved without any treatment.  
A few women with CIN grade 1 lesions can develop CIN grade 2 (Moderate) or 
CIN grade 3 (severe) or precancerous lesions, like adenocarcinoma in situ (AIS) 
 Without any treatment, there is high probability of the CIN2, CIN3 lesions 
developing into squamous cell cancer and of the AIS lesions developing into 
adenocarcinoma (Odendal L, 2011). 
Among the 13 HPV types considered “high risk”, subtypes 16 and 18 are 
considered the most dangerous: they cause approximately 70% of all cervical 
cancers worldwide.   
Non-oncogenic types of HPV (especially types 6 and 11) can cause genital warts 
and respiratory papillomatosis. Although these conditions very rarely result in 
death, they may cause significant morbidity and can incur substantial health-care 
costs, especially in industrialized countries (WHO Cervical cancer Human 
papilloma Virus (HPV) 2007). 
According to the Alliance for Cervical Cancer Prevention (ACCP) (Alliance for 
Cervical Cancer Prevention, 2011) “the most common HPV types, found in 91% of 
the cancers, were 16 (61%), 18 (10%), 45 (6%), 31, 33, 52, 35, and 58. Ninety 
percent of the specimens came from Europe, Asia, South and Central America; 
only 6% were from Africa”.  
Due to the poor condition of public health systems in Limited Resource Settings 
(LRS) and to the absence of public screening, diagnosis and treatment, 70% of 
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deaths occur in the developing countries. It is also disconcerting to see how little 
epidemiological information there is from LRS, considering the tremendous 
impact of HPV infection on public health, morbidity and mortality. 
Several estimates have been made of the epidemiologic impact of HPV in LRS.  
The United Nations has predicted a 40% increase of cervical cancer in the 
developing world by 2020. (United Nations, World Population Prospects. 2005) 
According to the GLOBOCAN 2002 figures, more than 80% of deaths from 
cervical cancer worldwide were estimated to be those in developing countries; in 
GLOBOCAN 2008, approximately 88% of deaths from cervical cancer occurred in 
the developing world. Unfortunately there is an increasing progression, which 
will reach at least 98% by 2030 (Ferlay J, Shin HR, et al 2008). 
The immune deficiency caused by HIV/AIDS is considered a risk factor for the 
progression of cervical cancer.( Palefksy JM, Minkoff H et al. 1999)  
The role and increase of HPV in HIV positive women will be further examined 
and discussed in the next chapter. 
 
 
 
1.2 HIV and HPV co-infection 
HPV/ HIV co-infection is a high risk condition for cervical cancer. Numerous 
studies, performed in the developed world, have clearly proven this risk (Goedert 
JJ, Cote TR, et al 1998, Mbulaiteye SM, Biggar RJ, et al.2003). 
Cervical cancer has been considered an “AIDS defining condition” in HIV positive 
women by CDC since 2008 (US Centers for Disease Control and Prevention 
(CDC).  
(AIDS-defining conditions. Morbidity and Mortality Weekly Report: 
Recommendations and Reports. 2008). 
It has also been demonstrated that HIV positive women are at  higher risk of HPV 
infection, than HIV negative women, (Palefksy JM, Minkoff H, et al 1999, Sun 
XW, Kuhn L et al 1997, Jamieson D.J., Duerr A., et al 2002, Moscicki A.B., 
Ellenberg J.H., et al 2000, Strickler H.D., Palefsky J.M., et al 2003) and of 
squamous cervical cancer. (Ellerbrock TV, Chiasson MA, et al  2000, Massad L.S., 
Riester K.A. et al 1999, Schuman P., Ohmit S.E., et al 2003). 
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An important study evaluating the increased risk of HIV acquisition in women 
with HPV was published recently (Houlihan C.F., Larke L.N., et al 2012). 
In  HIV positive women the risk associated with HPV infection, of any HPV 
genotype, was estimated to be quite consistent and statistically significant. 
(Auvert et al 2011)The authors also reported that HIV infection is twice as likely 
with high risk HPV genotype as compared to lower risk genotype (Auvert et al 
2011).  
HPV infection may appear similar to other Sexual Transmitted Infections (STI). 
Unfortunately HIV infection leads to a 5-fold increase in new multiple HPV 
infections within 6 months of seroconversion. (Wang et al 2011). 
Therefore we can assume that HIV infection could play a role in facilitating the 
HPV infection. It is also interesting to note that if this theory were validated, a 
possible vaccination program for HPV in this context, where the HIV prevalence 
is high could have a protective effect.  
Some authors are doubtful about the real impact of the co-infection of HIV/HPV 
on cervical cancer. Strickler ( Strickler HD, 2009) affirms that the co-infection of 
HIV and HPV has been demonstrated to cause a fivefold increase in cases of 
cervical cancer in patients living in Western countries but that this risk does not 
increase in time after the diagnosis of AIDS and with the CD4 cell count at the 
time of observation.  
Another author (Chaturvedi AK et al, 2009) registered an increased association 
between the two infections, but it was not statistically significant.  
These kind of results also lead one to consider the potential role of HAART, 
because it is considered to have a partial effect in restoring the immune system 
with a parallel increase of survival. According to these authors, this would allow 
such patients to reach an older age, when HPV related cancers reach their 
maximum prevalence. (Chaturvedi AK et al, 2009) 
The prevalence of different HPV genotypes also differs between HIV positive 
women and negative women. Luque (Luque AE, Jabeen M et al 2006) 
demonstrate that HIV positive women are infected with multiple HPV types and 
that the genotypes differ substantially from those of HIV negative women. 
Furthermore, other high risk HPV genotypes beside 16 and 18 are often found in 
this population, therefore representing an additional risk factor for cervical 
cancer.   
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This fact is due probably to the damaged immune system's lower capacity to 
control the expression and replication of HPV. HPV 16 is less common in this 
high risk population (Clifford et al 2006). 
Palefsky J. (Palesfsky J. 2006) also demonstrated that HPV 16 does not correlate 
with HIV infection in positive women as in the case of other oncogenic HPV 
types. The reason is primarily associated with the fact that HPV 16 may be 
counteracted less efficiently by the immune system than other types. HPV 16 is 
more frequent in women with higher CD4+ cell counts. (Palesfsky J. 2006) 
It seems that immune suppression due to HIV infection plays an important role 
in disease progression and pathogenesis (Palesfky J. et al 1998): HIV positive 
women were shown to have a fivefold greater risk of cervical cancer compared 
with the general population.  
Regarding the Pap test, HIV positive women are more likely to have abnormal 
Pap smear results than HIV negative women; The DIANAIDS study, performed 
in Italy, clearly demonstrated these results (Rezza et al 1997). The study 
demonstrated that 24% of HIV infected women have abnormal Pap smears 
compared with 8.9% of HIV negative women. Some groups also started to study 
the correlation between the frequency of HPV infections, CD4 cell count and viral 
load (Tornesello M.L., Duraturo M.L., et al 2008), showing a higher frequency of 
HPV infection with HIV-1 DNA levels >10,000 copies and statistically significant 
association (P<0.05).  
The connection between the association of CD4 cell counts and frequency of HPV 
infections, is also interesting, but only  at the higher levels of immunosuppression 
(CD4< 200 cells and CD4 between 200 and 500). This association is not 
statistically significant (P=0.208). (Tornesello M.L., Duraturo M.L., et al 2008). 
The association of a very high risk of cancer in the HIV population was studied in 
Italy. (Dal Maso L., Franceschi s., Polesel j., et al 2003). A large group of patients 
(over 12,000 patients) were monitored and observed.  
A significant increased risk of standard incidence ratio (SIRs) was observed for 
many kinds of cancer. The incidence of cervical cancer was 22 times higher that 
than in the general population. Therefore  it is clear that before the introduction 
of HAART, HIV seropositivity represented a very high risk factor. 
The association of CD4 cell counts and plasma HIV RNA levels appears more 
significant. Some studies were performed to check this correlation (Stricler H.D.  
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et al 2005) and they clearly demonstrate that plasma HIV RNA and CD4 cell 
count levels have a strong, statistical association in both the prevalence and 
detection of HPV. 
 The importance of improving the quality and the modality of  valid screenings for 
HIV positive women, as a high risk population, is clear.  
Nevertheless some studies reveal that there is no systematic approach and  
adequate scale. 
A study performed in Italy (Del Maso L. 2010) showed how access to the Pap 
smear for HIV positive women attending public health facilities, is occasional and 
not systematic even in Western countries. 
The modulation of the immune response to HPV is believed to play a critical role 
in controlling HPV infection, and presumably an effective cell mediated immune 
response to HPV is generated. (Palefsky J. 2006).  
Not enough is known of this immune response but HIV infection  most likely 
reduces the immune response to HPV infection. 
Local immunity is important. Levi demonstrated that the number of Langherans 
cells is diminished in women with HIV. Regulatory cytokines are down regulated 
in these women. (Levi et al. 2005) 
HPV infection could have a viral latency with persistence of the virus in the tissue 
for years. 
As already stated, HIV infection could lead to a fivefold increase in multiple new 
HPV infections within 6 weeks of HIV seroconversion With this association 
between the two infections (HPV and HIV) due to reverse causality, it is 
biologically reasonable to consider that prevalent HPV may increase the risk of 
HIV acquisition. (Wang C. et al 2011). 
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1.3 HPV infection, cervical cancer in women with HIV living in Africa  
As previously mentioned, cervical cancer is the leading cause of death among 
women in Africa (WHO Cervical cancer Human papilloma Virus (HPV), Geneva, 
2007).  
Women are more vulnerable than men to HIV/AIDS, and this fact exposes them 
to an increased risk. 
The tremendous impact of the disease is mostly due to the following factors: 
- a poor health system, which is  not able to prevent cervical cancer and offer 
women proper screening. 
- the burden of the HIV/AIDS pandemic, the consequences and  extent of which, 
will be discussed in the next paragraph. 
Several research groups have started studying the epidemiology and the clinic 
aspects of HPV infection in Africa, and are trying to learn how to manage the 
disease in this context. 
In 2001 Castellsaguè  published a study (Catellsaguè X., Menenndez C., et al  
2001) to detect the most commonly identified genotype in a group of HPV 
positive women in Mozambique.  
The results show that HPV genotype 16 is not the most common type. HPV 35 
was found to be the most common type among HPV positive women and women 
with cervical neoplasia. 
A study conducted in Mozambique by Magnano M. of this Doctorate School in 
BIOmolecular Sciences: “Human papillomavirus (HPV) genotypes and related 
abnormalities of cervical cytological results among HIV infected and HIV-
uninfected women in Mozambique”, showed that the patterns of the HPV 
genotypes circulating in Mozambique among HIV positive and HIV negative 
women are different from those in Western countries. 
This study shows that HPV was found in 159/191 (83.2%) subjects. HPV was 
found in 126/141 (89.4%) HIV-infected subjects and in 33/50 (66%) HIV-
uninfected subjects (p<0.001). In HIV-infected women there were 94/126 
(74.6%) HPV-multiple infections while in HIV-uninfected women there were 
22/33 (66.6%) HPV-multiple infections (p = 0.375).  
The most common types identified in HIV-infected subjects were HPV types 58 
(12.1 %, p <0.001), 16 (10.7 %, p = 0.06), 61(8.4 %, p <0.05), 53 (7.9 %, p = 0.55) 
and 6 (7.6 %, p = 0.413). The most common types identified in HIV-uninfected 
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subjects were HPV types 53 (10.4%), 6 (9.1%), 16 (9.1%), 18 (9.1%) and 66 (7.8%). 
Genotype 58 is highly associated with the HIV-positive status (p<0.001). This 
genotype was also identified as an important pathogen in previous studies in 
Mozambique, where it was identified in 100% of the cases of CIN 3 (Carrilho C et 
al., 2005). 
One of the topics still to be explored is HPV circulating genotypes and high risk 
genotype. Carrilho and al. (Carrilho C., Cirnes L a et al 2005) found high risk 
genotypes 16, 33, 35 and 58 in Mozambique cone biopsies. The patients were 
infected with multiple viral types.  
In Uganda another group of researchers (Odida M.,de Sanjosè S. et al 2008) 
found samples infected with high risk genotypes 16, 18, 31, 35, 39, 44, 45, 51 and 
52 in a cervical carcinoma archive. Only 3.7% of the samples had multiple 
infections. The samples come from the period between 1968 and 1992, so they are 
only partially related to the period of the spread of the HIV/AIDS pandemic. 
In these conditions, with no systematic screening programmes, it is easier to see 
the impact of the AIDS pandemic on cervical cancer in Africa. 
A study performed in Senegal (Rahabar A.R., Hawes S.E. et al 2007) clearly 
demonstrated how HIV infection reduces HPV clearance, especially for those 
whose CD4 cells level was < 200, therefore increasing the risk of cervical cancer. 
A group of researchers in Tanzania (Mwakigonia AR, Torres LM., et al 2012) 
studied a group of HIV infected women attending a CTC (Center of Treatment 
and Care) in Dar es Salaam, at the Mumbhili Hospital, and found that SIL and 
carcinoma were more frequent in the HIV positive group than in the HIV 
negative control case group, even though the result was not statistically 
significant. Other studies performed in Africa (Burkina Faso) demonstrated how 
HIV positivity itself represents a very high risk for cervical cancer (Didelot- 
Rosseau M-N., Nagot N., et al. 2006). 
Some groups also studied the impact of HIV 2 virus on HPV infection and lesions. 
(Hawes S.E., Critclow W.C., et al 2006). In Senegal this group proved that the 
HIV 2 group are apparently less likely to develop HISL than the HIV 1 group, but 
it is also correlated with the CD4 cell count (highest risk at <200) and high 
plasma HIV RNA level. 
Data published from various studies carried out in Africa (Tanzania) (Kahesas C., 
Mwaiselage J. et al 2008) confirmed that there is an association between the two 
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viral infections. Normally the prevalence of squamous cervical cancer among HIV 
positive women is  twice as high as among HIV negative women. 
In Uganda (Blossom D.B., Beigi R.H., et al 2007) a study was carried out on the 
prevalence of HPV infection, HIV infection and cervical cytological abnormalities 
in a group of women attending a sexually transmitted diseases clinic in the 
capital, Kampala, where HIV prevalence is high,  5-9.9 % (source: UNAIDS 
Epidemiological factsheet 2009). 
This study targeted a very high risk population and shows the epidemiology of the 
two co-infections. The HPV prevalence reported for this group of women was 
46.2%, with an HIV prevalence observed in this group of 34.9%. 
Genotypes 52, 58 and 16 were the most common genotypes detected, and 18% of 
the women were infected with the highest risk genotypes 16 and/or 18. 
The percentage of HIV positive women with abnormal Pap test results is also very 
high: 73% of this group of women compared to 16% of the HIV negative group of 
women.  
Similar results were obtained in South Africa, (Mbulawa Z.Z.A., Marais D.J., et al 
2012) where the HIV positivity status is associated with a 3 times increased risk 
of new HPV detection in women and a twice increased risk in men.  
As previously mentioned, HIV infection is also associated with a decreased HPV 
clearance rate. This fact exposes patients to a very high risk, because, as 
previously described, the pathogenesis of the disease is also associated with the 
presence of HPV. 
The influence of HIV 2 infection in cervical cancer is not yet clear. It is well 
known that the HIV pandemic is more common in West African countries than in 
East African countries. 
A study performed in Senegal (Langley C.L., Benga-De E., et al 1996) in a high 
risk  population, studied the prevalence of HPV infections, squamous 
intraepithelial lesions (SIL) and HIV 1 and HIV 2 infection. 
Co-infection with both viruses was associated with HPV infection. In  HIV 2 cases 
SIL were associated. It is not clear whether HIV 1 plays a more aggressive role in 
cervical cancer. 
Without starting a discussion here on the prevention and treatment of cervical 
cancer in Africa, it is interesting to study the research conducted in Botswana, 
which offers a picture of the complex situation of cervical cancer in the HIV 
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positive population living in Africa (Masire D.R., de Clerck R., Monare B., et al 
2012). A group of patients were studied in order to evaluate the efficacy of a 
treatment programme called “See and treat”, which is starting to be used quite 
frequently in Africa, and the percentage of HIV infected women recalled because 
of abnormalities was very high. 
Out of 2,175 patients screened, 1,347 had normal cytology at the first test. Seven 
hundred and nine of these women were recalled and required additional 
treatment for lesions. Overall, 264 of the total number of patients were diagnosed 
with cervical neoplasia and 6 with micro invasive cancer. This program could 
demonstrate the extent of the effect of the disease on public health in a setting 
like Africa. 
In South Africa, a recent paper (Omar T., Schwartz S., et al 2011) showed a cohort 
of HIV infected women who underwent regular Pap smear screening. They were 
observed over a period of time to check the regression of their cervical lesions. 
The findings were that HIV infected women have high rates of High Grade 
Squamous Intraepithelial Lesions (HSIL) and Low Grade Squamous 
Intraepithelial Lesions (LSIL) and a relatively low possibility of a return to 
healthy  condition. 
HAART was independently and statistically associated with a 28% decrease in the 
risk of progression. The risk of progression was twice as high in women with CD4 
<200. 
A recent study from Kenya (Mariah P, Mbuthia W. et al 2012) tried to identify 
risk factors for precancerous cervical cancer lesions among HIV infected women 
attending an ART clinic. 
The findings of the research were interesting in that the cervical precancerous 
lesions were associated with not being on ART treatment. 
The women with CD4 cell count levels below 200 were 1.6 times more likely to 
have precancerous lesions than those with cell counts over 200. 
Non ART patients were 2.2 times more likely to have precancerous lesions than 
those on ART treatment. These interesting data are quite similar to some of our 
findings, which will be discussed later on. 
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1.4 Status of the global HIV epidemic in sub-Saharan Africa and in Mozambique 
We now need to consider the HIV/AIDS pandemic in Africa and especially in 
Mozambique, in order to fully understand the interaction of the two viral 
infections and to try and understand the possible mechanism of their interaction. 
The following paragraphs therefore intend to offer a complete picture of the 
situation that we are exploring. 
It is well known that sub-Saharan Africa is at this time the epicentre of the 
pandemic.  
Source: http://www.unaids.org/documents/20101123_2010_HIV_Prevalence_Map_em.pdf 
 
Every year many international agencies provide up-to-date information on the 
state of the spread of HIV. 
UNAIDS (201207_FactSheet_Global_en.pdf, 2012) has published the latest 
information on the pandemic.  
It is important to point out that there has been a 20% increase in patients on 
HAART and that 1.7 million people have died of AIDS.  
Despite these high figures there has been a 25% decrease in mortality since 2005.   
Several studies performed in Africa (Jahn et al 2008, Palombi et al 2010) have 
confirmed these UNAIDS data. A large scale-up of treatment in this area was 
followed by a rapid reduction of mortality among a vulnerable population, the 
HIV positive population. This observation already gives us preliminary 
information on the possible effect of the massive use of HAART in Africa and the 
possible interaction of HIV with other diseases, especially malignancies 
associated with HIV infection.  
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Around 34 million people have been reported to be living with HIV/AIDS, more 
than ever before, due to the life prolonging effects of the antiretroviral therapy.  
These data also lead us to consider how the HIV/HPV co-infection in patients on 
HAART is affected by the treatment. 
Another important aspect has to be underlined. Young women (14-25 years old) 
account for 40% of  all women ages  for  new infections compared to men of the 
same age. Extremely high sensitivity to HPV infection, which goes with a high 
risk for HIV infection, could be the reason for the dramatic mortality due to 
cervical cancer registered at present in Africa. 
High quality treatment needs to be offered on a large scale in poor settings, where 
the population is very sick, which is what the DREAM programme does (M.C. 
Marazzi et al. 2005). This is a programme run by the Community of Sant’Egidio, 
a Catholic Community born in 1968 in Rome and present in over 72 countries 
throughout the world. 
 (See also: www.santegidio.org)  
In this programme, where this study was set up, we observe a fast recovery of 
patients who start HAART even at an advanced stage.  
The clear and solid evidence of this public health programme, run by the 
Community of Sant’Egidio in 10 African countries, convinced the International 
Community that investing in health programmes, targeted to address a rapid and 
high quality response, could save millions of people affected by the virus, and 
reduce transmission.  
This was especially clear in the maternal health sector with prevention of mother-
to-child transmission (PMTCT). 
The wide effect of this intervention, planned initially only to prevent the 
transmission from the mother to new born children, has also had a vast effect on 
maternal health and on the outcome of pregnancy (Marazzi et al, 2011).  
From this experience of treatment offered in 10 countries, including over 45,000 
patients on treatment in Mozambique and Malawi, we are starting to think that 
the introduction of HAART could also benefit the malignancies associated with 
HIV infection. 
 
UNAIDS estimates that by 2011, 8 million patients living in low and middle 
resource countries were receiving HAART. This is an incredible scale up of the 
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programmes which took the number from 300,000 in 2003 up to the present 
figures. It is the first time that an international effort has led to these results, and 
also to a dramatic reduction in the mortality rate of the countries which are most 
affected. 
The epidemiology of the disease shows that in 2011, 4.9 million [4.1 million-6.1 
million] young people (15-24) were living with HIV and 75% of them were living 
in sub-Saharan Africa. This also reflects the parallel infection of HPV and the two 
mortality curves due to the two infections, extremely clearly. 
In fact HIV is the leading cause of death of women of reproductive age. 
 
 
Source: UNAIDS 2012 Fact Sheet Global 
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However for a complete and updated picture of the epidemiology,  it is important 
to point out that the vulnerability of women and girls to HIV is still particularly 
high in sub-Saharan Africa; about 76% of all HIV-positive women in the world 
live in this region.  
In nearly all the countries in sub-Saharan Africa, the majority of people living 
with HIV are women, especially girls and women aged 15-24. In South Africa, the 
HIV prevalence among women aged 20-24 is approximately 21%, compared to 
about 7% among men in the same age range.   
It is also interesting to note that in sub-Saharan Africa, increased access to HIV 
treatment has reduced the number of people dying from AIDS-related causes, 
from an annual peak of 1.8 million [1.6 million – 1.9 million] in 2005 to 1.2 
million [1.1 million – 1.3 million] in 2011.   
This fact leads us to the consideration that HAART may strongly affect the 
epidemiology, not only of HIV/AIDS itself, but also of all the related diseases, 
including HPV. 
We also need to register an incredible step in the treatment in this area: nearly 
6.2 million people were receiving antiretroviral therapy in sub-Saharan Africa in 
2011, compared to just 100,000 people in 2003. 
Prevention through HAART has been demonstrated to be extremely effective. 
Several studies demonstrated with a mathematic model (Granich R, Crowley S et 
al 2009, Granich R., et al 2010) that administering HAART to a general 
population with HIV virus, decreased the infectivity of the population within a 
period of 10 years, contributing to lower the incidence and the number of new 
cases. 
Another very important study published recently, based on data collected in a 
real life cohort of patients on HAART in Malawi (L. Palombi L., Bernava G. M., 
Nucita A. et al. 2012), demonstrated that in a framework of five years we have 
seen a drastic reduction of new infections and a complete reversal of the trends of 
the pandemic in LRS. 
Prevention of mother-to-child transmission (PMTCT) remains the major 
challenge for intervention on HIV/AIDS in Africa. 
The graph below shows data on the PMTCT intervention and the objective to be 
reached by 2015. 
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In 2010 the WHO issued (WHO: Antiretroviral drugs for treating pregnant 
women and preventing HIV infection in infants Recommendations for a public 
health approach) their latest treatment guidelines, with two options for PMTCT 
interventions: Option A and Option B. These two options have created some 
confusion at a national level.  Together with the few HIV related services for 
maternal health, this is one of the greatest challenges that the international 
community is facing. Nevertheless the common intervention carried out by 
UNAIDS, WHO, UNICEF, and PEPFAR aims to eliminate new infections among 
children and keep the mothers alive. 
This research also aims to improve maternal health and cut the Maternal 
Mortality Rate (MMR) through targeted intervention on malignancies associated 
with HIV infections. 
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1.4.1 The Epidemiology of HIV/AIDS in Mozambique. 
Over the last two decades, the HIV epidemic in sub-Saharan Africa has triggered 
a widespread reversal in the population's health which, prior to HIV, had been 
improving significantly.  
The dramatic decline in life expectancy in countries with high HIV prevalence 
reflected the devastation caused by HIV/AIDS in Africa. Mozambique was 
particularly affected and was ill-prepared for the onset of HIV/AIDS. Twenty-six 
years of war had just come to an end, the health care system had completely 
fallen apart and there were no funds for rebuilding the country when HIV hit the 
population. HIV/AIDS was the tip of the iceberg in this scenario, as it increased 
the extent of underlying major health issues such as malnutrition, tuberculosis, 
malaria, gastrointestinal disease, inflated and already alarming health indices 
such as maternal and childhood mortality. Mozambique faced daunting 
challenges, including restructuring and rebuilding its health care system with 
very limited resources available to address the rising pandemic. Consequently, in 
the early 2000s the HIV epidemic found fertile ground in this environment. HIV-
1 prevalence rapidly increased throughout the country, facilitated by the Beira 
corridor (connecting Mozambique with Zimbabwe) in Central Mozambique, and 
the proximity of Mozambique to South Africa (Figure 1). 
Estimated HIV sero-prevalence 
among  adults 
by region of Mozambique
Central: 18 %
North: 9 %
South: 21 %
• 1.4 million Mozambicans  
living with HIV/AIDS
• Total population (2012)
22 million
Prevalence (2009) 13.6%
country wide
figure 1 
 
The population of Mozambique is estimated  to be  approximately 22 million 
people, 52% of whom are women. Most Mozambicans live in rural areas and 
survive on agriculture. Although Mozambique has achieved political stability and 
rapid economic growth in recent years, the HIV/AIDS pandemic represents a 
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major obstacle to successful development. Mozambique describes its HIV 
epidemic situation as severe. The UNAIDS Report on the Global AIDS Epidemic 
2010 estimated that in 2009, 1.4 million individuals were living with AIDS in 
Mozambique, 54% of the HIV-infected individuals were women and 9.3% 
children. The number of new infections in Mozambique in 2009 was reported at 
130,000 with an incidence rate of 
1.19% (15-49 years). Deaths due to 
AIDS in 2009 were reported at 96,000, 
and the number of HIV infected 
pregnant women was reported at 
149,000 for that year. AIDS orphans 
under 18 years in Mozambique in 2009 
were estimated at 670,000. 
Surveillance data from UNAIDS 
demonstrated an HIV prevalence of 
13.6% in 2009, significantly higher 
than the sub-Saharan average of 7.2%. 
In addition, the UNAIDS AIDS Day 
Report for 2011 demonstrated that 
although HIV incidence was declining 
in some African countries (Ethiopia, 
Nigeria, Botswana, and South Africa), 
in Mozambique the epidemic seemed 
to be levelling off at unacceptably high 
levels. According to national estimates, 
each day 444 Mozambicans become 
HIV-infected. As the population 
pyramid in Mozambique is comprised 
mainly of young individuals and life 
expectancy is less than 50 years of age, 
HIV/AIDS is wiping out the country 
and erasing a generation of young men 
and women 
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This data shows how the HIV/AIDS pandemic in Mozambique has reached its 
peak and the extent to which the disease is affecting the country. 
 
 
Source: 
 
This data clearly shows how the Southern Region, where we performed the study, is 
the region with the highest prevalence in the Country and how the disease is still  
rising. 
HIV prevalence among sexually active women of reproductive age, who are at a very 
high risk of HPV infection, is also very high. 
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From a public health perspective, access to Antenatal Care Services (ANC) and to the 
relative HIV/AIDS services for pregnant women, is a key intervention and could result in 
several outcomes: 
The first would be to guarantee childbirth in a health facility for safe deliveries, instead of 
delivering at home, thus dramatically decreasing the maternal mortality rate. Moreover, 
25 
 
improved access to the health services could increase the number of people accessing 
HIV/AIDS Voluntary counselling and testing services (VCT) and therefore HAART, for 
those who are HIV positive and eligible for treatment. 
 Cervical cancer screening could also be added to these services. 
 
These data encourage us to continue in this direction in order to try and mitigate the 
terrible impact of the HIV/AIDS pandemic on the general population of Mozambique. 
 
1.4.2 DREAM Programme  
DREAM in Mozambique: the DREAM programme in Mozambique, in collaboration 
with the Ministry of Health and the National health system, presently manages 10 heath 
care centres in the country, both in urban and in rural settings. DREAM centres have 
been set up throughout the country, from the north to the south, and they care for 
21,800 HIV-infected or affected patients, including 16,400 patients on HAART. The 
programme focuses in particular on saving mothers with HIV/AIDS and on the 
prevention of vertical HIV transmission. To date 10,600 women in Mozambique have 
received Prevention of Mother-to-Child Transmission (PMTCT) interventions during 
pregnancy through the DREAM programme. The HIV-1 transmission rate within the 
programme has been very low overall and has declined significantly over the years. A 
very significant reduction in maternal mortality has been registered among women 
receiving HAART for PMTCT purposes. Data presented at the IAS Conference in Rome 
in 2011 ( Liotta G., et al 2011) confirmed that this holistic approach to treating HIV/-
AIDS in this specific population has reduced maternal mortality dramatically to levels 
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below reported country rates for the general population (a ten-fold reduction from 
baseline). 
In July 2011, due to the programme’s significant presence in Mozambique and the 
outstanding results of our PMTCT approach, a Cooperative Agreement was signed 
between the Ministry of Health of the Republic of Mozambique and the DREAM 
programme. The objective of this agreement is to let the DREAM Programme assist the 
country in dealing with the medical emergency that MTCT of HIV has caused in 
Mozambique.  
The main areas of the Cooperative Agreement are:  
(1) Increase triple antiretroviral therapy for prevention of vertical transmission of HIV 
in Mozambique;  
(2) A strategy for countrywide implementation of nutritional supplementation to HIV-
infected pregnant women and their children;  
(3) Increase laboratory diagnosis and monitoring;  
(4) Training clinicians on HIV/AIDS;  
(5) Development of institutional support systems for health information;  
(6) Development of strategies for universal access to antiretroviral therapy.  
This agreement proposes the inclusion of strong community involvement, since a major 
and unique feature of the DREAM programme is the involvement of the entire 
community, including the patients themselves, who are active participants in their 
treatment process.  
At the DREAM centres many established patients are routinely involved in counselling 
and strengthening the adherence of new patients to their treatment regimens.  
These patients organize campaigns and events in the community and organize home 
care for the most vulnerable and fragile patients.  
Treatment of mothers is a special focus of the DREAM PMTCT model. The priority is 
treatment of pregnant women and the mother-infant couple, as we see this as a crucial 
step in ensuring Africa’s future. While therapy for individuals with HIV/AIDS aims to 
counter the progression of infection, the PMTCT programme aims to treat mothers, not 
only in order to prevent new infection but also to safeguard the infant’s health. Many 
studies have demonstrated that maternal health is directly associated with infant health, 
which is one reason why maternal health is one of UNICEF’s Millennium Development 
Goals. 
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 In the PMTCT programme, HIV-infected women are offered HAART from the 14th 
week of pregnancy if needed for their own health (CD4 cell count less than 350 
cells/mm3 or WHO clinical stage 3/4) or from the 25th week of pregnancy if prescribed 
for PMTCT purposes. Following delivery, all women on the programme continue 
HAART while breastfeeding (even if clinical, immunologic or virological eligibility 
criteria for HAART have not yet been satisfied). This therapeutic approach has led to 
highly successful infant and maternal outcomes at our African centres. Recently, the 
WHO introduced a triple-therapy HAART option for HIV-positive pregnant women, 
targeting both prevention of transmission to children and appropriate treatment of 
mothers (Maternal triple ARV prophylaxis to prevent MTCT – Option B) (WHO 2010). 
Infant prophylaxis in the programme consists of single dose of nevirapine provided as 
close as possible to birth, in any case within 72 hours. Infants are evaluated at the 
centres shortly after birth with physical examinations and by recording basic 
anthropometric parameters. If infants have low birth weight or demonstrate any other 
clinical problem, frequent clinical examinations are scheduled. A key element of the 
programme is also early virological diagnosis of infants, so that immediate HAART may 
be initiated if necessary to decrease the morbidity and mortality risk. DREAM centres 
are supported by their own molecular biology laboratories, which perform HIV DNA 
PCR testing of infant specimens by trained laboratory personnel from Mozambique. 
HIV b-DNA (Siemens) or PCR (Abbott) testing of infants is routinely performed at 1, 6, 
and 12 months of age and HIV-1 serology at 18 months.  
Nutritional supplementation to mothers and infants is a key component of the 
programme, not only for retention in care but also for improved health outcomes. 
Throughout pregnancy and until the child is 18 months old, the patients are guaranteed 
monthly food support (rice or maize, beans, peanuts, oil, sugar) and multivitamin 
supplementation. This measure counteracts malnutrition and anaemia and contributes 
to the reduction of premature deliveries and low birth weight in our patient population. 
In the postpartum period, nutritional supplementation also assists with infant 
development following weaning and contributes to maintaining adequate maternal 
caloric intake while breastfeeding. The programme also provides nutritional 
supplementation to all patients with a reduced BMI or an AIDS diagnosis.  
 
 
 
28 
 
1.5 Epidemiology of HPV infections and cervical cancer since the introduction of 
HAART  
The capacity of HAART to reduce mortality in the HIV positive population has been 
unequivocally demonstrated to be effective.( Palombi L, Dorrucci M, Zimba I et 
al. 2010) 
Since the introduction of HAART these benefits have also had an effect on other 
malignancies, like Kaposi Sarcoma (KS) and non Hodgkin’s Lymphoma (NHL) (J Natl 
Cancer Inst. 2000) 
The use of HAART in patients with HIV could have a beneficial effect on cervical cancer. 
(Adler D.H. 2010). 
This benefit has not been clearly demonstrated. In fact many authors (Adler D.H. 
2010).associate longer survival, due to HAART, with longer exposure to HPV infection, 
with an increased incidence of cervical cancer, together with partial restoration of the 
immune function. 
Chaturvedi (Chaturvedi et al 2009) studied the possible impact of HAART in the US, 
crossing the data from before and after the introduction of HAART in the US registry of 
cancer, and finding a non-statistically significant difference between the two periods, in 
AIDS patients and compared to the general population.  
A significant difference was found in cases of KS and NHL (Engels EA et al 2008), which 
decreased after the introduction of HAART. 
A similar observation was made in a study performed in Italy where in a cohort of 
21,000 AIDS patients the standardized incidence ratio (SIR) of cervical cancer 
decreased by a smaller proportion than KS or NHL.It is significant that there was no 
difference in the incidence of cervical cancer before and after the introduction of 
HAART. (Dal Maso L. et al 2009), 
Similar results were obtained in Switzerland by Clifford in the Swiss HIV Cohort study 
(Clifford et al 2005). 
The meta analysis of 23 prospective studies performed in Western countries in over 
47,000 patients, described in Highly active antiretroviral therapy and incidence of 
cancer in human immunodeficiency virus-infected adults, J Natl Cancer Inst 2000, 
showed that the introduction of HAART in this high risk population, lowered the 
incidence of KS and NHL down, but was not significant for the incidence of cervical 
cancer. 
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Despite these apparently clear results, the impact and the role of HAART in cervical 
cancer are not clear. 
We need to take several variables into account, like CD4 cells count level, viral load, type 
of HAART, adherence. 
In fact other groups, as well as ours, noted that there is a correlation between these 
variables and outcomes. 
Delmas studied a group of 485 HIV infected women and found that the group with CD4 
cell counts of less than 200 reported a prevalence of SIL which was double compared 
with the group with CD4 cells counts over 500 (Delmas MC, Larsen C et al  2000). Even 
if the specific effect of HAART was not studied, it is clear that a possible effect of 
restoring patients' immune capacity could led to an indirect reduction of the impact of 
HPV infection and of the incidence of cervical cancer. It is interesting that in the study 
there was no difference between the treated group and the untreated one regarding the 
persistence of HR HPV and rate of progression of SIL. This data, which is also 
confirmed in our experience, lead us to consider how HAART could have a protective 
effect on cervical cancer, or at least, block the evolution of the lesions to cervical cancer. 
The study does not clearly underline the role of the CD4 cell count and viral load, whose 
association could be important for understanding the role of HAART in the progression 
of lesions. 
Minkoff (Minkoff H. Ahdieh L. et al 2001) studied the effect of HAART on a group of  
women affected by the co-infection for a period of six months and report interesting 
results. 
Considering their CD4 cell counts and adjusting for them, there seems to be a regression 
of lesions in women on HAART. Moreover women on HAART have a reduced risk of 
progression. 
Other groups found similar results. Heard (Heard I, Tassie JM, Kazatchkine MD et al 
2002) published a study on a group of 168 women infected with HPV (96 of whom were 
on HAART) and found that by adjusting the data for the CD4 cell count for the patients 
on HAART, the regression of the disease was 1.93 times higher among the HAART 
group. This confirms a potential effect of the treatment and on progression of the 
disease. 
Controversial findings were reported by another group who disagree with the previous 
results. 
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Schuman, (Schuman P, Ohmit SE et al 2003) published data from a large cohort of 
women who underwent a periodic evaluation, for over 5 years. The findings do not show 
any potential benefits of HAART. In fact the women with low CD4 cell counts, that is 
those under treatment, do not have a decreased incidence of SIL. 
The controversial findings of the different research groups appear to focus on the 
HAART benefits, but it is clear that the role of the CD4 cell count “nadir”, at the 
beginning of the treatment, during the treatment and the VL value could make a 
difference. 
HAART seems to play a role in HPV clearance in women with pre-existing SIL but not 
for the group without SIL. Moreover HAART was not found to be associated with 
increased regression of cervical lesions (Lillo FB., Ferrari D., et al 2001). 
A recent study by Kang (Kang M., Cu-Uvin S., 2012) explored the correlation between 
the viral load (VL) and the level of CD4 cell count with HPV infection, in women on 
HAART. 
It is clear that this association of factors could play a role on the evolution of the lesions 
and on the persistence of HPV in the cervix. 
The researcher demonstrated that in 84% of the cases affected by both viruses the VL 
was  > 400 copies/ml. 
There was no significant difference between the group with VL > 400 copies and < 400 
copies in clearance of HPV. The women with a current CD4 cell count > 350 cells were 
more likely to clear the HPV virus than the women with CD4 cell count < 350 cells. 
These data could help us understand a possible role of HAART in the HPV co-infection, 
even though the study does not offer a clear picture of the possible mechanism of 
interaction of HAART.  
It is clear that the combination of VL, CD4 cell count and HPV detection could vary in 
relation to the different effects of the HIV RNA level on HPV prevalence and on the 
detection of incidence, depending on the CD4 cell count. High VL could be associated 
with HPV detection as a result of a possible interaction. 
In 2012 Adler published a paper (Adler  D.H., Kakinami L. et al 2012) to determine the 
real impact of HAART in the incidence and regression of lesions in HIV infected women. 
The study was performed in South Africa, Soweto on a cohort of infected women. 
This group of women were enrolled from 2003 to 2010 and consist in a large cohort of 
1,123 women under HAART following the South African HAART guidelines. The 
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researcher selected two groups of women, one not on HAART  and one on HAART, in 
order to evaluate the real impact of treatment. 
The group of women on HAART were less likely to progress, from cervical cancer smear 
results, than the other group, although the difference was not statistically significant. 
A statistical analysis performed on the two groups also showed that the group under 
treatment showed a greater regression of the cervical smear results. 
The final results are very interesting because the group under treatment is more than 
twice as likely to have a regression of cervical lesions. Furthermore the HAART group 
with normal smears are significantly less likely to have abnormalities in subsequent 
cervical smears. The authors conclude that, after years of observation on this large 
group of women, it is possible to affirm that HAART decreases the risk of cervical cancer 
among HIV infected women to that of the general population.  
Although these quite serious and convincing results, similar to our experience in 
Mozambique on a similar population, are not as uniform as those of the other group, 
they still make an important contribution. 
In a previous study the same author (Adler D.H. 2010) carried out an analysis of the 
different clinical studies performed to evaluate the impact of HAART in HPV infection. 
The author reviewed many of the last decade's studies and found several discordant 
results in support of or against the positive impact of HAART on HPV related cervical 
disease. 
Sometimes the differences are related to the different methodologies followed: some 
groups evaluated the lesions at the baseline and followed the patients in time. In some 
cases the patients with normal PAP smears among the participants were studied to 
check progression. Other groups followed women with pre-existing abnormalities and 
assessed the rate of progression or regression. 
The different findings also influenced the different recommendations that ensued. The 
American Cancer society suggested screening every three years. The US Centre of Public 
Health required two Pap test smears in the first year of diagnosis of HIV infection and 
annually afterwards. 
Palefsky (Palefsky J.M., 2003) published a paper where apparently there was no effect 
of therapy on the lesions. At the time he affirmed that since the therapy improved the 
life expectancy of the patients, that is their survival, it could cause more prolonged 
exposure to the virus. Moreover at that time he considered that the presence of the HIV 
virus alone was important but not essential for the development of high grade CIN or 
32 
 
cervical lesions. So, he concluded that HAART does not have a particular effect on 
progression or regression of high grade CIN or cervical lesions. 
The author stated that the introduction of the therapy did not reduce the prevalence of 
genital infection among the HIV positive women. He also found a correlation between 
the CD4 cell count and regression, observing how, after 5 months treatment with 
HAART, the median CD4 cell count increased. It was accompanied by a parallel 
regression of the lesions, suggesting a potential role of HAART inducing an immune 
reconstitution mechanism which could play an important role. 
So the therapy in this high risk group of women, who are exposed to a very high risk of 
cervical cancer, could play a protective, although modest role.   
Another group, (De Vuyst H. Lillo F. et al 2007) studied the effect and impact of HAART 
therapy, and the association with HPV infection, HIV and cervical neoplasia. 
They examined and compared several studies on this topic. 
The results showed that HIV positivity is linked with a stronger probability of having 
multiple HPV infections. (De Vuyst et al 2008). 
Moreover it was demonstrated that plasma HIV viral load and CD4 cell count in 
combination seem to have a stronger association with HPV incidence (Stickler et al 
2005). 
The researcher indicated that many different cohort studies show an increased SIL 
incidence rate in HIV–positive compared with HIV-negative women. 
Many groups reported an increased risk of cervical cancer in women with HIV living in 
Africa (Sitas et al 2000). 
Similar findings were reported by another group (Moodley et al 2005), again in South 
Africa, where the sero-prevalence of HPV in women with HIV was four times higher.  
These authors reported uncertain results regarding the effect of HAART on human 
papillomavirus infection.  
In fact in 2001 Minkoff et al showed that the women with HIV/AIDS on HAART had a 
40% SIL regression. 
The data on the effect of HAART on ICC from others studies reported in the same paper 
are incomplete and controversial. 
In 2009 Paramsothy P et al studied the effect of HAART on human papillomavirus 
clearance and cervical cytology. Five hundred and thirty-seven women were enrolled 
and they were followed up for 4 years. The results are encouraging because among 
women with pre-existing abnormal cervical cytology, HAART was associated with 
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enhanced HPV clearance. In fact ASCUS lesions and normal Pap test results were not 
associated with clearance of HPV due to HAART. 
It is clear that the study did not explore the effect of different treatment regimens and 
their possible interactions. Furthermore other associated factors, like adherence, were 
not investigated. 
Minkoff et al published an interesting paper in 2010, which continued to investigate 
other possible factors associated with use of HAART, like  adherence. 
The group examined a large cohort of 2,800 HIV positive and HIV negative women who 
underwent biannual examinations.  
The interesting feature was that they examined adherence to HAART, defined as a self 
reported >95% use of treatment as prescribed. The results were interesting as well: in 
the adherent group oncogenic HPV prevalence decreased by 36%, compared to 12% in 
the non-adherent group. Moreover the oncogenic HPV infection detection rate 
decreased by 33% in the adherent group compared to 9% in the non adherent group. On 
the other hand the difference in results regarding the incidence of SIL among adherent 
women compared to non-adherent women was not as marked. 
The authors conclude that the protective effect of HAART could be limited by longer 
exposure to oncogenic HPV. 
These data, collected in USA, do not entirely reflect the characteristics of African 
settings, where other conditions may affect the findings. 
Other studies also evaluated the effect of HAART on the HPV infection.  
In 2009 Fife K et al examined the prevalence of HPV in HIV positive women initiating 
HAART. The group studied the association between the prevalence of HPV DNA, the 
CD4 cells count and HIV viral load, after the response with HAART. 
The prevalence of cervical HPV DNA detection decreased from 66% at baseline to 49% 
after 96 weeks of treatment and the prevalence of HR type decreased from 62% to 39% 
in the same period. The decrease of high risk type was clearly demonstrated in this 
study; although in other studies it was not clearly demonstrated. 
The study underlines once more, the need to improve the number and quality of studies 
to be performed, especially in settings where cervical cancer is more prevalent, like in 
Africa. 
Palefsky (Palefsky JM 2003) studied the interaction of HAART and cervical 
intraepithelial neoplasia (CIN) with the HPV infection. The researcher is convinced that 
the HPV virus is essential but insufficient by itself  for the development of CIN. 
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Therefore  HAART may enhance the immune system efficency in patients co-infected by 
HPV and HIV, and other factors, not influenced by HAART, may play a role in the 
development of CIN. He reported that the wide use of HAART has not led to a decrease 
in persistence of HPV types.  HAART has contributed to improving CD4 cell counts in a 
group of patients in whom CIN lesions regressed; suggesting that loss of immune 
response and HAART induced reconstitution may play a role in protection against CIN 
(Heard I., Schmitz V. et al 1998). Even though the results are uncertain, a pattern 
emerges, revealing that a better response is seen in women with higher CD4 cell counts 
at the time of initiation than in those who respond to HAART with the largest increase 
in CD4 cell counts. These data also demonstrate the need to start HAART as soon as 
possible, because it may decrease the  mortality rate and in this case the morbidity rate 
as well.  
In 2011 Atashili et al. tried to evaluate the impact of HAART on cervical cancer mortality 
in HIV positive women, simulated in sub-Saharan Africa. They studied different 
scenarios in Cameroon between HAART initiation and cervical cancer screening. 
The findings revealed that the mortality rate of women on HAART, who are not 
screened for cervical cancer, is twice as high as of those not on HAART and not 
screened. 
It is clear that the findings are the results of statistical methods and that we need to 
perform a comparison with real life situations. 
 
 
 
2 Aim of the Research 
 
The aim of this study is to investigate the mid and long–term impact of HAART (Highly 
Active Antiretroviral Therapy) in a cohort of woman with Human Papillomavirus (HPV) 
and HIV in Mozambique.  
Because HAART lowers the HIV viral load, slows the progression of the HIV disease, and 
helps restore normal immune function, it has been hypothesized that HAART might 
enhance HPV clearance and the regression of cervical dysplasia.  
Another aim of the study is to continue the follow up of the HIV positive women enrolled 
in order to monitor the evolution of any lesions observed, the evolution of the Pap test in 
the HPV negative women, and to stratify the lesions in the HIV positive women according 
35 
 
to CD4, viral load and type of antiretroviral therapy for those in treatment. One of the 
research hypotheses of the study is to clarify whether the evolution of the lesions can also 
be influenced by the type of therapy. 
       
 
3. Methods            
3.1 Study population  
The participants were women initially attending the Health Centre in Benfica, a very 
populated area in the northern area of Maputo in Mozambique. The area is growing 
rapidly, due to the expansion of the city and the recent construction of the Olympic 
village and the new stadium, so that the centre is in a strategic position. Benfica 
Health Centre is a private health centre, integrated in the National Health System. 
Every DREAM centre provides health services free of charge for the general 
population attending the centre. The centre's staff include a coordinator (not 
necessarily a health professional),  a medical doctor (visiting - due to the scarcity of 
staff),  a clinical officer (Tecnico de medicina  in Portuguese - a health professional 
with a three year diploma), a pharmacist,  nurses,  counsellors and community health 
workers (the “activists”).  
Every centre is responsible for the treatment of around 3,000 patients, with an 
average increase of 70 new patients/ month. 
A clinical officer (tecnico de medicina) and a nurse are responsible for the study of 
HPV. 
In 2011, the centre was transferred to two new centres: Machava General Hospital 
(National Reference Hospital for TB) and “Centro para a Criança” specialized in 
treating the mother and child. On one hand, transferring the centre involved 
reorganising the patient flow, but on the other hand, it helped us think about the 
possibility of extending the screening programme in a public health perspective.  
Both centres are run by the Community of Sant’Egidio, within the DREAM 
programme. 
A gynaecologist from the Central Hospital of Maputo comes to the centre once a week 
to carry out the medical examinations and collect the Pap tests. This gynaecologist 
was trained in Pisa and another Italian gynaecologist spent some time in Maputo to 
teach the staff how to carry out the examination and how to perform the Leep 
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procedure. The entire team is linked with the group of pathologists from the Central 
Hospital of Maputo, which is responsible for diagnosis.  
 
 
3.2 Study design 
This is a prospective, two-arm, observational study. The first arm includes HIV- 
infected women in care for HIV/AIDS initially in the Benfica DREAM centres, and 
then in the Machava General Hospital DREAM centre and in the “Centro para a 
criança “DREAM centre of Maputo. This observational study continues the study that 
was started previously in the same cohort, which aimed to investigate the HPV 
genotypes present and the persistence and incidence of HPV in these patients. 
The enrolment period lasted 12 months (1st January 2009 - 31st January 2010). The 
observation period of this research was 36 months while the follow up will continue 
for 15 years. The protocol was approved by the Minister of Health in Maputo in May 
2007. 
 
3.3 Selection of participants 
The cohort of women is the same as the one selected for previous studies. Starting 
from August 2007, HIV- infected women and a control group of HIV negative women 
between the ages of 15 and 50, were invited to take part in the research. Health 
education meetings were organized in order to promote the women’s participation. 
Participation was on a voluntary basis. All the HIV negative women were invited to 
take the rapid HIV test before inclusion in the study. Written informed consent was 
requested.  
 
3.5 Collection of specimens, procedures  
For each woman enrolled, the gynaecologist collected two cervical samples using an 
Ayre spatula and cytobrush. The samples were collected by scraping each woman’s 
uterine cervix, both the ecto and the endocervix, and the cells were then spread onto 
slides (Pap smears). The slides were sent to the Central Hospital of Maputo where they 
were read by pathologists at the Department of Pathology. The results were reported 
according to the CIN classification and then according to the Bethesda System: Pap 
Smears were considered to be abnormal if they contained ASCUS or LSILs or HSILs. 
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Depending on the results of the Pap test, the women were recalled for a control, or to 
undergo colposcopy or conization. The programme then included the possibility of 
offering the women with AIS lesions a Leep intervention in the Central Hospital free of 
charge (a group of gynaecologists was trained for this procedure in Pisa and a 
gynaecologist from Pisa offered a period of “on the job “training in Maputo)   
All the women enrolled followed the programme, also in order to design a possible 
screening programme to be offered in Africa. 
The program was established and agreed with direction of the Central Hospital (see 
protocol attached). 
All the women who accepted to take part in the operational research were aware that 
they had to attend a follow-up for the following 15 years. 
The frequency of gynaecological visits and Pap tests depends on previous Pap test 
results, HIV status, HPV status and the HPV genotype. 
Patient follow-up in the HPV Study 
1) If the Pap test is negative 
a) HIV-uninfected women who are HPV-negative come back for a Pap test and 
gynaecological visit after 12 months then, after the first year, every 24 
months. 
b) HIV-uninfected women who are HPV-positive come back for a Pap test and 
gynaecological visit every 12 months. 
c) HIV-infected women: 
i. If the CD4 cell count is >500 cells/mm3 and CV<100,000 
copies/ml, they go for a 
(2) Pap test and a gynaecological visit every 12 months. 
i. If the CD4 cell count is between 300 cells/mm3 and 500 cells/mm3 
or CV>100,000, they go for a Pap test and gynaecological visit 
every 12 months. 
ii.If CD4 cell count is <300 cells/mm3 and HPV is negative or positive 
to a low or undetermined type, they go for a Pap test and 
gynaecological visit every 6 months. 
iii. If the CD4 cell count is <300 cells/mm3 and HPV is positive to a 
high-risk type, they go for a Pap test and gynaecological visit every 
6 months. 
2) If the Pap test is positive: 
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a) HIV-uninfected women and HIV-infected women with an ASCUS/LSIL 
result and CD4 cell count >300 cells/mm3 and CV < 100,000 copies/ml are 
sent for colposcopy. If they do not need treatment, they continue follow-up 
and go for a pap test and 
(3) Gynaecological visit every 6 months. 
(4) HIV-infected women with an ASCUS/LSIL result and CD4 < 300 cells/mm3 or 
CV > 100,000 copies/ml are sent for colposcopy, biopsy and if necessary, 
treatment. If they do not need treatment, they continue follow-up and go for a 
Pap test and gynaecological visit every 6 months. 
b) HIV-uninfected women and HIV-infected women with an HSIL result are 
sent urgently for treatment. 
 
The study was difficult because of the mobility of patients and the fact that the centre 
was transferred in 2011 to 2 different treatment centres. The data we present reflect 
this "real life" challenge that we had to deal with. 
 
 
3.6 Laboratory procedures in HIV patients 
HIV rapid tests: Two rapid test methodologies were used: Determine and Unigold 
(Rouet et al., 2004). 
Peripheral blood CD4+ and CD8+ cell counts were determined by flow-cytometry - 
Becton Dickinson (Glencross DK et al., 2008). Characterizing cells at different stages 
of development through the use of fluorescent-labelled monoclonal antibodies against 
surface markers is one of the most common applications of flow-cytometry. T cells 
have become a dynamic area of research. Among the methods used to characterize this 
major lymphocyte subset, multicolour flow-cytometry is preeminent. Additionally, the 
complexity of the CD3+ T-cell population—both functionally and phenotypically makes 
multiparametric flow-cytometry a necessary and powerful platform. An accurate CD4 
T-cell count is essential for correct clinical management of HIV/AIDS patients, for 
their staging and their monitoring under HAART treatment. The CD4 cell count is also 
essential for prevention and treatment of opportunistic infections (OI) (in fact starting 
prophylaxis against Pneumocystis pneumonia (PCP) is suggested for those whose CD4 
cells counts are < 200 cells.)   
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The study uses the FACSCalibur TM system an automated bench top flow-cytometry 
system that offers three or four-colour capability and can perform both cellular 
analysis and optional cell sorting with automated pipetting and analysis.  
In this study we used two systems for measuring the viral load: 
- branched DNA (bDNA) assays - System 340, version 3.0; SIEMENS Diagnostic. Viral 
quantification or viral load testing has become part of the routine management of 
patients infected with HIV-1 or hepatitis C virus (HCV). Several molecular technologies 
are currently available for the clinical laboratories. Of these, only the bDNA assays are 
FDA-approved for HIV-1 and HCV viral load testing. This signal amplification 
technology is based on a series of hybridization reactions that can be fully automated 
and thus lessen the amount of labour required to perform this type of analysis. 
- Abbott RealTime HIV-1 assay, an in vitro reverse transcription-polymerase chain 
reaction (RT-PCR) assay for the quantization of Human Immunodeficiency Virus type 
1 (HIV-1) on the automated m2000 System or with m24sp extraction in human plasma 
from HIV-1 infected individuals with over 40 to 10,000,000 copies/ml. The Abbott 
RealTime HIV-1 assay is intended for use in conjunction with clinical presentation and 
other laboratory markers for disease prognosis and for use as an aid in assessing viral 
response to antiretroviral treatment, measured by changes in plasma HIV-1 RNA 
levels. 
HIV plasma viral loads, CD4+ T-cell counts and antiretroviral therapy regimens were 
obtained from the patients’ records available from the DREAM Programme in 
Mozambique, and performed in the DREAM laboratories located in Maputo. 
 
 
 
4. Results            
Three hundred and nineteen (319) women were enrolled ( 236 HIV positive and 83 
HIV negative ): 236 HIV positive(74.0%) (mean age 35.4 SD±7.7) and 83 HIV 
negative(26.0%) (mean age 35.6 SD± 9.9). The differences between the ages of the 
two groups was not significant (t-test 0.131; p=0.91); however table 1 reports the age 
distribution of the sample: the most represented age is the intermediate age (26-45) 
in both groups even if the percentage of total women is quite different (80.8% in the 
HIV positive group vs 65.9% in the HIV negative (X2 7.5, p=0.021). All patients 
came to the health centre for reasons not related to cervical cancer.  
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Table 1: Age distribution according to HIV status 
   
Age 
   0-25 26-45 45+ Total 
HIV NEG N 13 54 15 82 
%  15,9% 65,9% 18,3% 100,0% 
POS N 19 189 26 234 
%  8,1% 80,8% 11,1% 100,0% 
Totale N 32 243 41 316 
%  10,1% 76,9% 13,0% 100,0% 
 
 
In table 2 we can see the prevalence of HPV positivity in the cohort. HPV positivity 
was reported in 67.7% of the cases among the two groups of women enrolled for the 
study.  
 
Table 2 – Cumulative Prevalence of HPV infection 
  Frequency % 
 Positive 216 67,7 
Negative 103 32,3 
Total 319 100,0 
 
 
Table 3-5 describes the results of HPV tests according to the different Pap tests performed 
during the time of observation. We can see that, even though the numbers of each sample 
varies, according to the observation, the percentages do not varies significantly.  
 
Tab 3 Prevalence of HPV Infection at PAP test 1 
  Frequency % 
 POSITIVE 210 68,0 
NEGATIVE 99 32,0 
Total 309 100,0 
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Tab 4 Prevalence of HPV Infection at PAP test 2 
  Frequency % 
 POSITIVE 112 81,2 
NEGATIVE 26 18,8 
Totale 138 100,0 
 
Tab 5 Prevalence of HPV infection at  PAP test 3 
  Frequency % 
 POSITIVE 49 94,2 
NEGATIVE 3 5,8 
Totale 52 100,0 
The cumulative prevalence of HPV infection was  67.7% (table 6), 51.8 % and 73.3 % in the 
HIV negative and HIV positive patients respectively (X2= 12.9; p< 0.001).  The distribution 
shows a clear  association between HIV and HPV infection. Odds  Ratio for HIV condition 
was highly significant, showing a substantial risk reduction in HIV negative women 
(OR=0.39 ; CL: 0.23 -  0.65) 
 
Table 6 – Cumulative prevalence of HPV infection according to HIV status 
   HPV 
   Positive Negative Total 
HIV NEG N 43 40 83 
%  51,8% 48,2% 100,0% 
POS N 173 63 236 
%  73,3% 26,7% 100,0% 
Total N 216 103 319 
%  67,7% 32,3% 100,0% 
 
 
 
 
This is further confirmed by the association between HIV infection and higher 
prevalence of advanced cervical lesion as showed in tables 7-9.The first Pap test 
shows ( tab 7)  that the percentage of the most severe lesions (CIN2/3) is 4.8% 
and 1.2 % among the HIV positive and HIV negative respectively. Chi square 
on the entire distribution was 2.1 (p=0.54). 
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Table 7.  
Distribution of cervical lesion grading at first Pap Test according to HIV 
status 
   PAP1 
   CIN2/3 CIN1/HPV Celulas atipicas NEG Total 
HIV NEG N 1 15 5 60 81 
%  1,2% 18,5% 6,2% 74,1% 100,0% 
POS N 11 39 15 163 228 
%  4,8% 17,1% 6,6% 71,5% 100,0% 
Totale N 12 54 20 223 309 
%  3,9% 17,5% 6,5% 72,2% 100,0% 
 
 
 
 
At the second Pap test ( tab 8) the prevalence of CIN/2/3 was  3.4% among  HIV 
positive and HIV negative patients (Chi square on the distribution= 2.2, p=0.53) . 
Finally a similar percentage can be observed at the third Pap test.( tab 9) 
Although these results do not show statistic significance, they seem to suggest the 
impact of HIV infection on HPV status, as already observed in several studies. 
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Table 8 
Distribution of cervical lesion grading at second Pap Test according to HIV status 
   PAP2 
   CIN2/3 CIN1/HPV Celulas atipicas NEG Total 
HIV NEG N 0 2 1 18 21 
%  ,0% 9,5% 4,8% 85,7% 100,0% 
POS N 4 23 6 84 117 
%  3,4% 19,7% 5,1% 71,8% 100,0% 
Totale N 4 25 7 102 138 
%  2,9% 18,1% 5,1% 73,9% 100,0% 
 
 
Table  9 
Distribution of cervical lesion grading at third  Pap Test according to HIV status 
   PAP3 
   CIN2/3 CIN1/HPV Celulas atipicas NEG Totale 
HIV NEG Conteggio 0 2 0 4 6 
% entro HIV ,0% 33,3% ,0% 66,7% 100,0% 
POS Conteggio 2 10 4 30 46 
% entro HIV 4,3% 21,7% 8,7% 65,2% 100,0% 
Totale Conteggio 2 12 4 34 52 
% entro HIV 3,8% 23,1% 7,7% 65,4% 100,0% 
 
 
The potential role of HAART: 
To evaluate the possible effect of HAART in this high risk group, tables 10-12 show the 
distribution of patients according to both HIV status and HAART at the three different Pap 
test times and evaluations. The number of  HIV positive patients on HAART varies in the 
three Pap tests. This is because some of the patients (namely the HIV positive patients who 
did not need HAART for their own health) suspended the antiretroviral treatment when 
their children  completed weaning according to the PMTCT DREAM protocol (Tab 10-12).  
 
 
44 
 
Table 10 HIV Status and HAART  at PAP test 1 
 Frequency % 
 HIV NEG 83 26.0 
HIV POS not on HAART 72 22.6 
HIV POS on HAART 164 51.4 
Total 319 100.0 
 
Table 11 HIV Status and HAART at PAP test 2 
 Frequency % 
 HIV NEG 21 15.2 
HIV POS not on HAART 18 13.0 
HIV POS on HAART 99 71.8 
Total 138 100.0 
 
Table 12 HIV Status and HAART at PAP test 3 
 Frequency % 
Valid HIV NEG  6 11.5 
HIV POS not on HAART 7 13.5 
HIV POS on HAART 39 75.0 
Total 52 100.0 
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We hypothized  that the role of HAART in controlling HPV infection and its consequences 
was the recovery of the immune system. To explore this hypothesis we studied the HPV 
status in association with CD4 cell count.  
The following tables (Tab. 13) including CD4 cell count Status (<200 or >200), HAART 
condition and HPV status show that in both HAART strata HPV infection is higher  in 
individuals with an impaired immune system with less than 200 CD4 cell count 
(respectively 100% vs 73% ).   
 
 
 
 
 
 
 
 
 
 
 
Tab 13 Cross Tab CD4 cell count Status, HAART condition and HPV status 
No HAART 
HPV POS 
Total No Yes 
CD4 <200 N 0 4 4 
%  / 100.0% 100.0% 
>200 N 14 38 52 
%  27.0% 73% 100.0% 
Total N 14 42 56 
%  77.2% 22.8% 100.0% 
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Furthermore we stratified the cohort of HIV positive patients according to the CD4 
cell counts and the grading of the  cervical lesions observed. Table 14 shows the 
correlation between the low  CD4 cell count and cervical lesions. In the table we 
divided the two sub group according to the CD4 cell count level(>200<) and in the 
four grade of cervical lesion observed. (The orange columns -< 200 CD4 cells/mm3- , 
and the yellow ones - >200 CD4/mm3 cells- represent the 100% of the cases  of the 
two subgroups). The risk increases in patients with less than 200 CD4 cells was very 
high (X2=14.362; p=0.02). 
This observation could lead us to think that the low  CD4 cell count could be 
considered as a risk factor for cervical cancer. The role of the integrity of immune 
system of the patients, its role to protect from other viral infections and  the 
potential positive impact of HAART on the severity of HPV lesions could have a 
strong effect on the progression of the cervical disease. 
 
Table 14 Correlation of CD4 cell counts and grade of cervical lesions 
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Tables 15-17 show the frequency of conization. Conization could be taken as an indication 
of the severity of the detected lesion of the cervix. Again conization is more frequent in HIV 
positive women not on HAART than in those on HAART. In table 15 we can observe the 
frequency of conization in the whole cohort. 
 
Table 15 Frequency of conization in the cohort 
Conization  Frequency % 
 Yes 19 6.0 
No 300 94,.0 
Total 319 100.0 
 
In table 16 we can see that in the HIV positive group conization is more frequent than in 
the HIV negative group, (7.3% vs 2.4%) again suggesting that the HIV positive status is a 
predisposing factors for more advanced HPV lesions.  Some patient were lost to follow up 
and therefore the total number is lower than the cohort. 
 
Tab 16 Conization and HIV status 
 
HIV 
Total Neg Pos 
Conization Yes Number 2 17 19 
%  2,4% 7,3% 6,0% 
No Number 81 217 298 
%  97,6% 92,7% 94,0% 
Total Number 83 234 317 
%  100,0% 100,0% 100.0% 
 
In table 17 we explored the role of CD4 cell count in association with the conization 
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Table 17  Conizations by CD4 cell count 
 
   Conization 
   YES NO Total 
HIV+ Population Below 200 CD4 N 3 20 23 
%  13,0% 87,0% 100,0% 
Above 200 CD4 N 11 173 184 
%  6,0% 94,0% 100,0% 
Total N 14 193 207 
%  6,8% 93,2% 100,0% 
 
 
As shown  in the previous table the percentage of conizations was twice as much in the 
lower CD4 stratum (13.0 vs 6.0). 
Assuming that the length of HAART can play a critical role in the recovery of immune 
system we analyzed the mean HAART exposure in days in 2 subgroups: patients with sever 
lesions vs HPV negative patients.( tab 18). We do not consider the  CIN 1 subgroups  in 
order to evidence the effect of HAART treatment on the most severe  cervical lesions.   
 
Table 18  Mean HAART days exposure in CIN2/CIN3 patients vs PAP test negatives 
patients 
 
 PAP1 N Media St Deviation. Error std. Media 
 CIN2/3 10 251,0000 432,63097 136,80992 
NEG 143 478,4336 575,58638 48,13295 
The result is that negative patients had a mean HAART days exposure substantially higher 
than the CIN2/CIN 3 carriers. 
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In the next table 19 we can observe the cohort of HIV positive women who underwent  
conization, stratified by HAART status. From this preliminary data it seems that the 
group on HAART, underwent conization less frequently than the non HAART group. 
Again the suggestion is that HAART could play a role in limiting the progression of HPV 
lesions. It is worth noting that the HAART group is the one with a lower baseline CD4 
count and  higher viral load than the group without HAART treatment.   
 
Table 19 HIV Pos Group: HAART and Conization  
 
Coniz 
Total YES NO 
HIV POS Not on HAART  Number 8 73 81 
%  9.8% 90.2% 100.0% 
POS on HAART>30 
days 
Number 9 144 153 
%  5.8% 94.2% 100.0% 
Total Number 17 217 234 
%  7.3% 92.7% 100.0% 
 
 
 
Chi-square 
 Value df p 
Pearson's Chi-square 13,382 2 0.001 
N.  234   
 
 
The univariate analysis shows a significant association between HIV status and baseline 
viral load with HPV status.( tab 20) HIV negative status seems to reduce prevalence of 
HPV  lesions as well as lower HIV viral load.  However this association  is not confirmed by 
the multivariate analysis ( tab 21).In fact the only factor that shows a  mild statistic 
significant association with the presence of HPV lesions is a CD4 Cells count lower than 
200/mm3..  The lack of association between HIV status  and the presence  of HPV lesions 
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could be due  the positive impact of HAART that lower the risk of onset of HPV lesions 
through the reinforcement of immune system. Although our data does not support a clear 
relation between HAART and better outcome of HPV infection , this association could be 
indirectly suggested by the above results regarding the CD4 cell count. The main limitation 
of this analysis is the lack of information on the sexual behavior of the patients. We are not 
able to classify the sample according to the age of the first sexual intercourse, the 
frequency of sexual intercourse  and the use of condoms, which are related to the incidence 
and prevalence of HPV infection 
 
Tab 20 Logistic univariate regression 
 
P. RR 
95% CI per RR 
Lower Upper 
 Age ( ) 0.744 0.919 0.553 1.526 
CD4 cell count (>200 vs <200) 0.122 1.225 0.947 1.585 
HIV POS not on HAART  1.000     
HIV NEG 0.016 0.460 0.245 0.863 
HIV POS on HAART 0.798 1.072 0.628 1.830 
Baseline Viral Load (<400; 401-10000; >10000) 0.018 1.333 1.050 1.691 
  
Tab 21 Logistic multivariate  regression 
 
P. RR 
95% CI per RR 
Lower Upper 
 
Age class 0.677 0.894 0.526 1.518 
HIV Pos not on 
HAART 
0.216 
1.000 
  
HIV Neg 0.099 0.522 0.241 1.130 
HIV Pos not on 
HAART  
0.687 1.129 0.627 2.031 
Baseline VL 0.857 1.031 0.736 1.446 
Baseline CD4 cell 
count 
0.051 2.176 0.997 4.749 
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5. Discussion  
Our results show that HPV infection and severe associated lesions dramatically increase in 
an HIV positive African population.  
Clinical operational research on the impact of HAART on HPV has conflicting results. 
Some authors (Lillo et al. 2001) showed that there is no variation in disease progression 
between the HAART group and the non HAART group. Similar finding were reported by 
Schuman (Schuman et al 2003). In 2009 Paramsothy found that HAART enhanced HPV 
clearance but does not increase cervical disease regression. 
Other researchers on the other hand, reported that HAART decreases the prevalence of SIL 
from 69 to 53% (Heard I et al 1998). The same authors (Heard I et al 2002) demonstrated 
that disease regression was twice as high among those on HAART treatment, in 
comparison to those not on HAART. Similar findings were reported in another study 
(Ahdieh – Grant et al. 2004), where regression of SIL was observed among HAART 
patients. Furthermore Del Mistro et al. in 2004 demonstrated a regression of SIL among 
HAART users. (Del Mistro A, Bertorelle R et al. 2004) 
Our results confirm that HAART may play an adjuvant  role  in recovering the immune 
system  in the very high risk population, such as  HIV positive women. However, it is 
possible that previous studies did not properly assess the role of time exposure to 
treatment. Till now, guidelines did not recommend triple therapy during pregnancy in 
asymptomatic women with high CD4 cell count. I surmise that this has created conflicting 
results when examining our patients by rough HAART status. Only after an adequate 
estimate of HAART treatment-time, its real role has emerged. These data can be explained  
by the strong, independent and significan association with CD4 cell count both for severe 
lesions and conization.  
In 2007, Soncini et al. found that HAART significantly reduces the risk of developing 
cervical disease, as we have found in our research.( Soncini E, Zoncada A, Condemi V. et 
al.2007) 
To fully understand the protective role of HAART on cervical disease it is probably also 
important to investigate the different type of regimens, to check whether any class of 
antiretrovirals available at the moment plays a relevant role. It is well known that in 
Kaposi Sarcoma (KS), protease inhibitors based regimens are more efficient than the other 
HAART regimens in stopping progression of the Sarcoma. 
One limitation of our study is that it was designed as an observational study in real life 
settings in Mozambique. 
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The protocol and the screening programme performed during the study could be 
improved. Another limitation of the study was that during the first stage, the samples had 
to be sent to Italy to perform the HPV genotype. This caused a delay in receiving the results 
and consequently also a clinical delay in the patients' therapy. The possibility of 
performing the test locally could also improve- in the near future- the undertaking and 
adherence of  patients to the screening program. 
The introduction of HAART is improving both the quality of life and the survival of 
patients living in LRS.  
These data confirm that HAART could  play a protective role-together with prevention 
measures and surgery, especially at the first stage of the cervical disease- onset  the cervical 
cancer. 
The ultimate step of the fight against cervical cancer is the possibility of offering 
chemotherapy for those who, due to late diagnosis or rapid progression, are in need of 
treatment. 
   
 
 
6. Conclusions 
1. HPV infection is associated with HIV infection  
2. Among HIV positive women the progression of HPV lesions towards the more advanced 
stage is associated with lower CD4 cell count that is typically underline progression of HIV 
AIDS disease  
3. Preliminary data suggest that HAART treatment, contributing to a recovery of immune 
system, seems to be able to play a critical  role against the progression of HPV lesions in 
HIV positive women  
 
 
 
7. Perspective   
This research offers a possible perspective to the public health approach. Systematic HPV 
screening in a high risk population is not a reality at the moment in Africa. The need to 
evaluate a feasible model is therefore quite topical and is necessary. This experience, 
combined with the experience of the DREAM programme, could offer us a possible way 
forward and a therapeutic solution for this high risk group of patients. 
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The research has made it possible to train a group of gynaecologists from the central 
Hospital of Maputo to use the Leep technique in Pisa at Sant’Anna Hospital, for treating 
women affected by AIS. 
From the perspective of laboratory diagnostics the research has contributed to developing 
a new generation of pathologists and has provided the possibility of setting up a specialized 
laboratory for the genotypization of HPV in the most important hospital in the country.  
The agreement, signed with the Central Hospital of Maputo, is attached.  
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Ao Dr Momede Rafico Bagus 
Director Clinico  
HOSPITAL CENTRAL DE MAPUTO 
 
Objecto: Formalização do programa de Prevenção do Cancro do Útero nas 
mulheres HIV positivas e descrição dos pontos focais.  
 
1.Introdução 
Em 2007 a Comunidade Santo Egídio iniciou um estudo ciêntifico pela prevenção do 
Cancro do Útero com o Hospital Central de Maputo e o Hospital Universitário de PISA em 
Itália. O estudo foi autorizado pelo MISAU, do Comité Nacional de Bioética para Saúde de 
Moçambique e da Direcção de Saúde da Cidade de Maputo.(mettere data) 
O estudo foi conduzido desde Setembro de 2007 a Fevreiro de 2011. Cerca de 300 
mulheres (220 tem HIV Positivas e 80 HIV Negativas), participaram no estudo. Analizados 
os resultados, sintetizados no Report anexado, propõem-se a continuação  em  forma de 
um programa de saude publica estruturado e continuo. Este programa clinico serà 
conduzido no contexto do Programa DREAM de prevenção e tratamento do HIV SIDA em 
Moçambique. 
 
2. Intituições Participantes 
a) DREAM – Associação Para o Direito aos Tratamento Sanitários e de Luta Contra a Sida  
b) Departamento de Ginecologia e Obstetricia HCM 
c) Departamento de Anatomia Patalogica HCM 
d) Departamento de Ginecologia Obstetricia do Hospital de Pisa (ITALIA) 
e) Departamento de Anatomia Patalogia de Pisa (ITALIA) 
 
3. População alvo: 
Mulheres HIV Positivas de 15 a 55 anos de idade. 
 
4. Objectivos 
a) Prevenção e tratamento das lesões do cancro do utero na população alvo; 
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b) Redução a pelo  menos 90% da  mortalidade por esse tipo de cancro nas mulheres HIV-
positivas que padecem da doênça; 
c) Avaliar a eficacia e a eficiência de um programa de prevenção do cancro do útero no 
contexto do serviço Sanitario National. 
 
5- Metodologia  e Pontos Focais 
Programa de saúde pública no contexto do programa DREAM  no Serviço Sanitario 
Nacional. O programa serà conduzido tanto em termos de actividades clinicas e de 
educação a saude, tanto em termos de pesquiza operacional.   
 
Funções específicas e responsabilidades das instituições envolvidas 
 
DREAM – Associação Para o Direito aos Tratamentos Sanitários e de Luta Contra a Sida  
No Centro DREAM  as mulheres HIV positivas participam todos os meses em diferentes 
actividades médicas e de educação a saúde no contexto do programa de prevenção e 
tratamento do HIV/ SIDA segundo  protocolos planificados. O protocolo de prevenção do 
cancro do útero será incorporado no contexto dos protocolos de atendimento de HIV/SIDA 
que as mulheres já estão a fazer. O Centro DREAM vai  ser equipado com enfermeira SMI  
treinada para realizar  aconselhamento ginecológico  e testes de Papanicolau.  
 
 
Departamento de Ginecologia de HCM 
 
a) Treinamento  da enfermeira SMI do Centro DREAM  sobre a correcta execução técnica 
do Pap testes.  
 
b)  Identificação e diagnóstico colposcópico das eventuais lesões cancerígenas presentes 
c)  Tratamento médico e cirúrgico de lesões cancerosas em pacientes do  programa 
DREAM  no Departamento de Ginecologia de HCM. 
 
O acesso das pacientes do programa DREAM ao diagnóstico colposcópico e ao tratamento 
médico – cirúrgico das lesões cancerígenas é específico e dedicado como previsto pelo 
acordo de doação do sistema LEEP-surgery estipulado entre o Hospital Universitário de 
Pisa e o Hospital Central do Maputo por ocasião da doação a este último da metodologia 
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LEEP. As pacientes do programa DREAM serão acompanhadas ao Departamento de 
Ginecologia do HCM pela Enfermeira SMI do Centro DREAM nos dias e horários 
concordados com os médicos do Departamento.  
 
Departamento de Patologia do HCM  
a) Leitura ao microscopio das almostras. 
b) Colaborção com os medicos patologistas do Hospital de Pisa.  
 
Deapartamento Laboratorios do HCM 
a) Realizacoes dos  esames de biologia molecular para a identificação dos genótipos de 
HPV. 
b) Colaboracao com os biologos do laboratorio em Pisa 
 
Departamento de Ginecologia Obstetricia do Hospital de Pisa (ITALIA) 
a) Colaboração com os medicos ginecologistas do HCM. 
b) Treinamento dos medicos ginecologistas do HCM  sobre o diagnostico e a correcta 
execução técnica do tratamento de cirurgião com metodologia de electrocoagulação 
(LEEP).  
 
Departamento de Patologia do Hospital de Pisa  
a) Controlo de qualidade da leitura do Pap test realizada pelo medicos dos Departamento 
de Patologia do HCM. 
b) Controlo de qualidade dos esames de biologia molecular para a identificação do 
genótipos de HPV. 
 
Potocolo da prevenção do câncro do útero 
O método de diagnóstico do programa de prevenção inclui o estudo da célula com a leitura 
do exame de Papanicolau que é o estudo da biologia molecular para a caracterização do 
genótipo de HPV. O protocolo é baseado nos resultados do estudo preliminar do programa 
já realizado e inclui a execução de pelo menos um Pap test por ano em mulheres HIV-
positivas e HPV-positivas e a execução de pelo menos um teste de Papanicolau cada três 
anos nas mulheres  HIV-positve e HPV-negativos. 
 
Tempo e Lugar 
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Propõem-se  iniciar o programa de Prevenção do Cancro do Utero a partir de Novembro de 
2011 no “Centro para Criança”  na  Avenida  Eduardo Mondlane em Maputo.   
 
 
Composição do grupo de trabalho:  
Programa DREAM:  
Dr Massimo Magnano San Lio – Responsavel pelo Programa de Prevenção do Cancro do 
útero. 
Prof. Leonardo Palombi 
Prof. Maria Cristina Marazzi 
Dra Ines Zimba 
Dra Noorhjia Magid 
Dra Paola Germano 
Dr Giovanni Guidotti 
 
Departamento de Ginecologia e Obstericia HCM: 
Dr  Elias Suizane F Wale- Responsavel pelo Departamento de Ginecologia e Obstericia 
HCM 
Dra Magda  
Dra Manuela Cunha 
Dra Ines Bonaventura 
Dr Bizeque 
 
Departamento de Anatomia Patologica HCM 
Dra Carla Carrilho - Responsavel pelo Departamento de Anatomia Patologica HCM 
Dra Cesaltina Lorenzoni 
 
Departamento de Ginecologia e Obstericia -  Hospital de Pisa 
Prof Andrea Genazzani- Responsavel pelo  controlo de qualidade 
Dr Fabio Taponeco  
 
 
Departamento de Anatomia Patologica - Hospital de Pisa 
Prof Generoso Bevilacqua- Responsavel pelo controlo de qualidade 
Pro. Giuseppe Naccarato 
Dr Ivo Marchetti 
Dra Maria Pia Cioni 
 
Composição do grupo que partecipa ao Comitè Clinico na Direção Clinica do HCM 
- Dr Massimo Magnano San Lio – Médico especialista em Higiêne , Epidemiologia e Saúde 
Pública – Doctor PHD em Oncologia Espermental e Molecular – Programa DREAM 
- Dr Elias Wale – Médico Especialista em Ginecologia e Ostetricia – Departamento de 
Ginecologia e Obstetricia HCM.  
- Dra Carla Carrilho – Médico Especialista em Anatomia Patlogica- Departamento de 
Anatomia Patologica HC 
